Prodrug-activating systems in suicide gene therapy
Top Cited Papers
Open Access
- 1 May 2000
- journal article
- review article
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 105 (9) , 1161-1167
- https://doi.org/10.1172/jci10001
Abstract
No abstract availableThis publication has 31 references indexed in Scilit:
- Gene delivery from replication-selective viruses: arming guided missiles in the war against cancerJournal of Clinical Investigation, 2000
- Patent property of suicide gene therapy involving prodrugs 1996 - 1999Expert Opinion on Therapeutic Patents, 1999
- The bystander effect in the HSVtk/ganciclovir system and its relationship to gap junctional communicationGene Therapy, 1998
- Enhancement of the Herpes Simplex Virus Thymidine Kinase/Ganciclovir Bystander Effect and Its Antitumor Efficacy In Vivo by Pharmacologic Manipulation of Gap JunctionsHuman Gene Therapy, 1998
- Double Suicide Gene (Cytosine Deaminase and Herpes Simplex Virus Thymidine Kinase) but Not Single Gene Transfer Allows Reliable Elimination of Tumor CellsIn VivoHuman Gene Therapy, 1998
- Gene-Directed Enzyme Prodrug TherapyBioconjugate Chemistry, 1998
- Gene-directed enzyme prodrug therapy: quantitative bystander cytotoxicity and DNA damage induced by CB1954 in cells expressing bacterial nitroreductaseGene Therapy, 1998
- A cell surface tethered enzyme improves efficiency in gene-directed enzyme prodrug therapyNature Biotechnology, 1997
- VDEPT: An enzyme/prodrug gene therapy approach for the treatment of metastatic colorectal cancerAdvanced Drug Delivery Reviews, 1995
- Expression of the bacterial nitroreductase enzyme in mammalian cells renders them selectively sensitive to killing by the prodrug CB1954European Journal Of Cancer, 1995